Dr Damien Cullington

Consultant in Adult Congenital Heart Disease

Area of expertise

Adult congenital heart disease
Acute, chronic and advanced heart failure
End of life and palliative care
Evidence based cardiology


MBChB (Hons), University of Liverpool 2002
MRCP (London), 2005.
MD, University of Hull, 2013
Entry onto GMC specialist register, 2015
Fellow of the European Society of Cardiology, 2016

See Publications

  • Double jeopardy.
    Cullington D, Dunford N, Beer S, Hobson N, Chattopadhyay S, John J.
    Indian Heart J. 2013 May-Jun;65(3):315-8.
  • Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?
    Cullington D, Goode KM, Clark AL, Cleland JG.
    Eur J Heart Fail. 2012 Jul;14(7):737-47.
  • Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMART-AV: QLV substudy, SHIFT: echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update.
    Cleland JG, Coletta AP, Cullington D, Castiello T, de Boer RA, Clark AL.
    Eur J Heart Fail. 2011 Dec;13(12):1376-80.
  • Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D, Goode KM, Cleland JG, Clark AL.
    Heart. 2011 Dec;97(23):1961-6..
  • Impact of applying NICE guidance for the assessment of stable chest pain in rapid access chest pain clinics in a DGH: a service evaluation.
    Chattopadhyay S, George A, Anwar T, Advani K, Cullington D, John J.
    Int J Cardiol. 2011 Oct 6;152(1):135-9.
  • Unmasking the truth.
    Cullington D, Esmail S, Hurren S, Cleland JG, Clark AL, Alamgir MF.
    BMJ Case Rep. 2011 Jan 12;2011:
  • Structured telephone support or telemonitoring programmes for patients with chronic heart failure.
    Inglis SC, Clark RA, McAlister FA, Ball J, Lewinter C, Cullington D, Stewart S, Cleland JG.
    Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007228.
  • Digoxin: quo vadis?
    Cleland JG, Cullington D.
    Circ Heart Fail. 2009 Mar;2(2):81-5.
  • Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Cleland JG, Coletta AP, Clark AL, Cullington D.
    Eur J Heart Fail. 2009 Jun;11(6):622-30.
  • Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF.
    Coletta AP, Cullington D, Clark AL, Cleland JG.
    Eur J Heart Fail. 2008 Dec;10(12):1264-7
  • Cardiac resynchronization therapy: dyssynchrony imaging from a heart failure perspective.
    Cleland JG, Cullington D, Khaleva O, Tageldien A.
    Curr Opin Cardiol. 2008 Nov;23(6):634-45.
  • Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452.
    Coletta AP, Cleland JG, Cullington D, Clark AL.
    Eur J Heart Fail. 2008 Sep;10(9):917-20.
    Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE.
    Cleland JG, Coletta AP, Yassin A, Hado H, Cullington D, Abdellah AT, Clark AL.
    Eur J Heart Fail. 2008 Jun;10(6):614-20.
  • Cardiac resynchronisation therapy upgrade and occurrence of ventricular arrhythmia.
    Cleland JG, Cullington D, Abdellah AT.
    Heart. 2008 Jun;94(6):793;
  • Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy.
    Cleland JG, Coletta AP, Abdellah AT, Cullington D, Clark AL, Rigby AS.
    Eur J Heart Fail. 2008 Jan;10(1):102-8.
  • Emery-Dreifuss muscular dystrophy with cardiac manifestations.
    Cullington D, Pyatt JR.
    Br J Hosp Med (Lond). 2005 Nov;66(11):642-3